TP53 and soft tissue sarcoma: Therefore, these results demonstrate that a combined Cre-loxP and CRISPR-Cas9 system that activates KrasG12D and deletes Trp53 in KC mice is sufficient to result in primary soft tissue sarcomas with mutational load and CNV similar to an established Cre-loxP tumour model.